Karimah S. Bell Lynum, PharmD

Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, New Jersey

  • 3Articles
  • 13KReads
  • 2021–2026Active
  • 14Collaborators
  • 3Citations

About

Karimah S. Bell Lynum, PharmD, is affiliated with Otsuka Pharmaceutical Development & Commercialization Inc. in Princeton, New Jersey. Lynum has published research focused on schizophrenia, schizoaffective disorders, and bipolar disorder, including studies on aripiprazole once-monthly treatment and paliperidone palmitate compared with oral antipsychotics. The work spans clinical evaluations of treatment efficacy and safety, with particular attention to Black/African American patient populations. Lynum’s contributions appear in Psychiatrist.com from 2021 to 2026.

Publications

JCP
NNT, NNH, and LLH for Aripiprazole Once-Monthly in Schizophrenia
Original Research

NNT, NNH, and LLH for Aripiprazole Once-Monthly in Schizophrenia

May 13, 2026

Data demonstrate a favorable benefit-risk profile for aripiprazole once-monthly 400 vs placebo in acute and maintenance treatment of schizophrenia.
, , , et al
JCP
Safety and Efficacy of Maintenance Treatment with Aripiprazole Once-Monthly in Black/African American Adults With Bipolar I Disorder
Original Research

Safety and Efficacy of Maintenance Treatment with Aripiprazole Once-Monthly in Black/African American Adults With Bipolar I Disorder

March 9, 2026

The safety and efficacy of AOM 400 were comparable between Black/African American and non-Black/African American patients with bipolar I disorder
, , , et al
JCP
Original Research

Paliperidone LAI vs Oral Antipsychotics in African American Patients With Criminal Justice System Involvement

February 23, 2021

This study examined the use of injectable paliperidone palmitate in Black/African American patients with schizophrenia and prior criminal justice system involvement. Read it to see if treatment failures were...
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe